These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20434707)

  • 1. Closing in on the unknown enemy.
    Gnant M; Dubsky P
    Lancet Oncol; 2010 May; 11(5):402-3. PubMed ID: 20434707
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells in breast cancer: fiction or reality?
    Cristofanilli M; Reuben J; Uhr J
    J Clin Oncol; 2008 Jul; 26(21):3656-7; author reply 3657-8. PubMed ID: 18640950
    [No Abstract]   [Full Text] [Related]  

  • 4. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
    Bedard PL; Body JJ; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Sep; 27(25):4043-6. PubMed ID: 19652062
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant bisphosphonates for early-stage breast cancer.
    Brufsky A
    Lancet Oncol; 2011 Jul; 12(7):610-1. PubMed ID: 21708345
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisphosphonates in the adjuvant treatment of early breast cancer: conclusion.
    Eiermann W
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S16-7. PubMed ID: 20427028
    [No Abstract]   [Full Text] [Related]  

  • 8. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role for bisphosphonates in cancer management.
    Chlebowski RT
    Breast Dis; 2011; 33(2):55-7. PubMed ID: 22142659
    [No Abstract]   [Full Text] [Related]  

  • 10. Bisphosphonates in adjuvant treatment of early breast cancer.
    ; Harbeck N; von Minckwitz G; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S1. PubMed ID: 20427026
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
    Junker N; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 13. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
    Diel I; Aebi S
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
    [No Abstract]   [Full Text] [Related]  

  • 14. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
    Gnant M; Eidtmann H
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
    Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
    Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
    [No Abstract]   [Full Text] [Related]  

  • 16. [The ex-vivo culture of circulating tumor cells: a real hope for personalized therapy?].
    Larsen CJ
    Bull Cancer; 2014 Nov; 101(11):997. PubMed ID: 25580499
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?
    Clemons M; Russell K; Costa L; Addison CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):453-7. PubMed ID: 22562125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphonates in oncology].
    Soltau J; Medinger M; Unger C; Drevs J
    Med Monatsschr Pharm; 2003 Dec; 26(12):411-7. PubMed ID: 14699777
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone targeted therapy in breast cancer: present and future.
    Huober J; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
    [No Abstract]   [Full Text] [Related]  

  • 20. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells.
    Dalle Carbonare L; Valenti MT; Azzarello G; Balducci E; Crepaldi G; Realdi G; Vinante O; Giannini S
    Mol Cell Endocrinol; 2005 Aug; 240(1-2):23-31. PubMed ID: 15978718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.